| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_938a6d7a15cbc93a74abe1953eb25d47 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-07 |
| filingDate |
2007-03-09^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2011-10-18^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f2b7e55408a6686465f30962526e05e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b044871d84f3f92e40d373aacb442b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a66a3bb7341011ffad54416f15eed25a |
| publicationDate |
2011-10-18^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8039623-B2 |
| titleOfInvention |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| abstract |
The present invention relates to compounds of formula I: n nor a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8871904-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011104115-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8314141-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009143312-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8217048-B2 |
| priorityDate |
2003-10-10^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |